- Home
- PCT vs AUPH Comparison
PCT vs AUPH Comparison
Compare PCT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCT
- AUPH
- Stock Information
- Founded
- PCT 2015
- AUPH 1993
- Country
- PCT United States
- AUPH Canada
- Employees
- PCT N/A
- AUPH N/A
- Industry
- PCT Environmental Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- PCT Utilities
- AUPH Health Care
- Exchange
- PCT Nasdaq
- AUPH Nasdaq
- Market Cap
- PCT 1.1B
- AUPH 999.8M
- IPO Year
- PCT N/A
- AUPH 1999
- Fundamental
- Price
- PCT $5.99
- AUPH $7.75
- Analyst Decision
- PCT Strong Buy
- AUPH Strong Buy
- Analyst Count
- PCT 4
- AUPH 2
- Target Price
- PCT $12.50
- AUPH $11.50
- AVG Volume (30 Days)
- PCT 2.6M
- AUPH 1.3M
- Earning Date
- PCT 05-06-2025
- AUPH 05-01-2025
- Dividend Yield
- PCT N/A
- AUPH N/A
- EPS Growth
- PCT N/A
- AUPH N/A
- EPS
- PCT N/A
- AUPH 0.04
- Revenue
- PCT N/A
- AUPH $235,133,000.00
- Revenue This Year
- PCT N/A
- AUPH $11.86
- Revenue Next Year
- PCT $26.46
- AUPH $24.96
- P/E Ratio
- PCT N/A
- AUPH $193.75
- Revenue Growth
- PCT N/A
- AUPH 33.97
- 52 Week Low
- PCT $4.50
- AUPH $4.71
- 52 Week High
- PCT $15.58
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- PCT 38.86
- AUPH 46.63
- Support Level
- PCT $5.90
- AUPH $7.59
- Resistance Level
- PCT $6.66
- AUPH $7.83
- Average True Range (ATR)
- PCT 0.71
- AUPH 0.35
- MACD
- PCT 0.02
- AUPH -0.02
- Stochastic Oscillator
- PCT 29.14
- AUPH 65.84
About PCT PureCycle Technologies Inc. Common stock
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.